Trial Outcomes & Findings for Comparison of Isovue 370 vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA) (NCT NCT02171247)

NCT ID: NCT02171247

Last Updated: 2014-08-15

Results Overview

Contrast-to-noise ratios (CNRs) were calculated as follows: CNR = (vascular attenuation - myocardium attenuation) / SD of mean noise attenuation.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

35 participants

Primary outcome timeframe

during scan, approximately 3 hours

Results posted on

2014-08-15

Participant Flow

35 subjects signed consent. 2 subjects were not assigned to a arm and were withdrawn from study due to impaired renal function. 33 subjects completed the study.

Participant milestones

Participant milestones
Measure
Visipaque 320
Standard protocol is Visipaque 320. Visipaque 320: Visipaque 320 is standard protocol.
Isovue 370
Isovue 370 is a contrast agent with increased iodine concentration. Isovue 370: Isovue 370 is a contrast agent with increased iodine concentration.
Overall Study
STARTED
16
17
Overall Study
COMPLETED
16
17
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Comparison of Isovue 370 vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Visipaque 320
n=16 Participants
Standard protocol is Visipaque 320. Visipaque 320: Visipaque 320 is standard protocol.
Isovue 370
n=17 Participants
Isovue 370 is a contrast agent with increased iodine concentration. Isovue 370: Isovue 370 is a contrast agent with increased iodine concentration.
Total
n=33 Participants
Total of all reporting groups
Age, Customized
18 years and older
16 participants
n=5 Participants
17 participants
n=7 Participants
33 participants
n=5 Participants
Sex: Female, Male
Female
5 Participants
n=5 Participants
6 Participants
n=7 Participants
11 Participants
n=5 Participants
Sex: Female, Male
Male
11 Participants
n=5 Participants
11 Participants
n=7 Participants
22 Participants
n=5 Participants
Region of Enrollment
United States
16 participants
n=5 Participants
17 participants
n=7 Participants
33 participants
n=5 Participants

PRIMARY outcome

Timeframe: during scan, approximately 3 hours

Contrast-to-noise ratios (CNRs) were calculated as follows: CNR = (vascular attenuation - myocardium attenuation) / SD of mean noise attenuation.

Outcome measures

Outcome measures
Measure
Visipaque 320
n=16 Participants
Standard protocol is Visipaque 320. Visipaque 320: Visipaque 320 is standard protocol.
Isovue 370
n=17 Participants
Isovue 370 is a contrast agent with increased iodine concentration. Isovue 370: Isovue 370 is a contrast agent with increased iodine concentration.
Contrast to Noise Ratio
18.6 CNR
Standard Deviation 5.2
20.5 CNR
Standard Deviation 4.5

PRIMARY outcome

Timeframe: during scan, approximately 3 hours

Depiction of Branch Vessels - coronary branch depiction was performed as consensus decisions of two blinded radiologists. Criteria used was abscence or presence of vessels.

Outcome measures

Outcome measures
Measure
Visipaque 320
n=16 Participants
Standard protocol is Visipaque 320. Visipaque 320: Visipaque 320 is standard protocol.
Isovue 370
n=17 Participants
Isovue 370 is a contrast agent with increased iodine concentration. Isovue 370: Isovue 370 is a contrast agent with increased iodine concentration.
Image Quality
Conus
43.8 % of coronary branches visualized
94.1 % of coronary branches visualized
Image Quality
Sinoatrial Nodal
37.5 % of coronary branches visualized
82.4 % of coronary branches visualized
Image Quality
Diagonal1
87.5 % of coronary branches visualized
35.3 % of coronary branches visualized
Image Quality
Diagonal1 and Diagonal2
12.5 % of coronary branches visualized
64.7 % of coronary branches visualized
Image Quality
Obutse Marginal1
68.8 % of coronary branches visualized
29.4 % of coronary branches visualized
Image Quality
Obutse Marginal1 and Obutse Marginal2
6.3 % of coronary branches visualized
70.6 % of coronary branches visualized
Image Quality
Acute marginal1
62.5 % of coronary branches visualized
47.1 % of coronary branches visualized
Image Quality
Acute marginal1 and Acute marginal2
18.8 % of coronary branches visualized
52.9 % of coronary branches visualized
Image Quality
Septal perforator
43.8 % of coronary branches visualized
88.2 % of coronary branches visualized
Image Quality
Posterolateral
6.3 % of coronary branches visualized
64.7 % of coronary branches visualized

PRIMARY outcome

Timeframe: during scan, approximately 3 hours

Population: Data was not collected and therefore not analysed

The outcome will be measured by individual scores. The scores from multiple readers will be averaged.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: during scan, approximately 3 hours

The investigator will measure the length of visualized coronary artery for the left anterior descending, left circumflex and right coronary arteries as a way of quantifying visualization of distal coronary segments.

Outcome measures

Outcome measures
Measure
Visipaque 320
n=16 Participants
Standard protocol is Visipaque 320. Visipaque 320: Visipaque 320 is standard protocol.
Isovue 370
n=17 Participants
Isovue 370 is a contrast agent with increased iodine concentration. Isovue 370: Isovue 370 is a contrast agent with increased iodine concentration.
Attenuation of the Ascending Aorta and Coronary Arteries
ascending aorta
19.5 CNR
Standard Deviation 4.8
21.6 CNR
Standard Deviation 4.2
Attenuation of the Ascending Aorta and Coronary Arteries
coronary arteries
18.4 CNR
Standard Deviation 5.3
20.3 CNR
Standard Deviation 4.6

Adverse Events

Visipaque 320

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Isovue 370

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Daniel T Boll, MD

Duke University Medical Center

Phone: 919-684-2711

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place